Clearmind Medicine announces results of shareholders meeting

Clearmind Medicine announced that all of the matters put forward before shareholders for consideration and approval at its meeting held on November 14, 2023, as set out in the Company’s Management Information Circular dated October 9, 2023, were approved by the requisite majority of votes cast at the Meeting, including a resolution fixing the board of directors at four members, the election of directors of the Company for the ensuing year, a resolution to establish and approve an omnibus equity incentive plan and a resolution approving the directors to effect a consolidation of the common shares in the capital of the Company on the basis of fifty pre-Consolidation Shares for one post-Consolidation Share, or such other lesser consolidation ratio as determined by the Company’s board of directors at its sole discretion, in one or more tranches during the twelve months immediately following the Meeting.